Loading company…
Pairidex provides personalized molecular testing and residual disease monitoring for blood cancers.
Founded in 2023 by Andrew Young and based in Missouri, Pairidex develops FusionMRD™ molecular diagnostics for blood cancer monitoring. Paul Kortschak is CEO. In July 2026, it raised USD 4.89 million in seed funding from BioGenerator and other unspecified investors. The funding will support commercial launch, clinical studies, laboratory operations and platform development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in